Our Expert Network

  1. AI Agents Are Only As Good As The RNA Knowledge Behind Them 9/3/2026

    The RNA field is producing extraordinary volumes of information. Yet, giving an AI system access to more information does not necessarily make the system more scientifically intelligent.

  2. Will 2027 See A Meteoric Rise Of Programmable Nanomedicine? 9/2/2026

    The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic.

  3. From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2) 8/26/2026

    Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.

  4. Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics 8/19/2026

    Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.

  5. Drugging The tRNA Control System 8/19/2026

    Drug discovery has usually treated transfer RNA as cellular infrastructure: indispensable, highly conserved, and therefore dangerous to perturb. That description is accurate but incomplete. 

  6. Analytical Platforms: The Foundation Of The Next Generation Of RNA Therapeutics 8/11/2026

    RNA therapeutics are entering a new era where analytical platforms drive scalability, regulatory confidence, manufacturing flexibility, and the development of increasingly complex products.

  7. A New Purification Strategy For The Removal Of dsRNA Impurities From IVT mRNA Products 8/10/2026

    NIST research introduces a gentle SEC method that separates dsRNA impurities from IVT mRNA by tweaking buffer pH, achieving 81.8% target recovery without transcript damage.

  8. The Second Holy Grail Of Gene Editing: Large Knock-Ins 8/10/2026

    Exploring the race to achieve large gene knock-ins, emerging editing platforms, and how overcoming this challenge could unlock therapies for many inherited diseases.

  9. The Preclinical Gauntlet: Securing Capital And Designing Regulatory Pathways For Ultra-Rare ASO Drugs (Pt. 2) 8/7/2026

    SynaptixBio CEO Dan Williams explains why funding, regulatory strategy, toxicology, and disciplined execution — not just science — determine success in advancing ultra-rare ASO therapies.

  10. Bridging The Atlantic: A European Executive's Guide To Building A Successful U.S. RNA Business (Pt. 2) 8/6/2026

    European RNA biotech leaders can accelerate U.S. success by aligning fundraising, partnerships, manufacturing, hiring, and regulatory strategy from day one.